BioCentury
ARTICLE | Politics, Policy & Law

Levitating Levin: new chair’s ambitious plans to elevate BIO

How BIO’s new chair, Jeremy Levin, plans to smooth the path for innovation

June 7, 2019 11:49 PM UTC

Jeremy Levin has been talking for years about ways to elevate biopharma business practices and public policy to bypass obstacles that hold back biomedical innovation. As BIO’s new chair, he has a chance to try to persuade his colleagues to put those ideas into practice.

Guiding BIO has never been easy, but Levin, chairman and CEO of Ovid Therapeutics Inc., is taking on the task of chairing the organization at a particularly challenging time. ...